IC
Ikarian Capital Portfolio holdings
AUM
$302M
This Quarter Return
+7.96%
1 Year Return
+65.21%
3 Year Return
+441.33%
5 Year Return
+548.26%
10 Year Return
–
AUM
$322M
AUM Growth
+$322M
(+0.48%)
Cap. Flow
-$129M
Cap. Flow
% of AUM
-40.09%
Top 10 Holdings %
Top 10 Hldgs %
44.05%
Holding
134
New
20
Increased
8
Reduced
29
Closed
9
Top Buys
| 1 |
Viridian Therapeutics
VRDN
|
$11.4M |
| 2 |
Ultragenyx Pharmaceutical
RARE
|
$9.94M |
| 3 |
Arcus Biosciences
RCUS
|
$9.16M |
| 4 |
Spyre Therapeutics
SYRE
|
$8.89M |
| 5 |
Avalo Therapeutics
AVTX
|
$8.7M |
Top Sells
| 1 |
CYBN
Cybin
CYBN
|
$121M |
| 2 |
Sarepta Therapeutics
SRPT
|
$18.7M |
| 3 |
Soleno Therapeutics
SLNO
|
$11.3M |
| 4 |
Nuvalent
NUVL
|
$10.2M |
| 5 |
Crinetics Pharmaceuticals
CRNX
|
$8.27M |
Sector Composition
| 1 | Healthcare | 99.61% |
| 2 | Real Estate | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Tarsus Pharmaceuticals
TARS
$2.47B
| $33.9M | 4.73% | 1,030,277 +230,000 | +29% | +$7.56M |
|
|
2
Crinetics Pharmaceuticals
CRNX
$2.92B
| $21.8M | 3.04% | 426,913 -161,905 | -27% | -$8.27M |
|
3
Enliven Therapeutics
ELVN
$1.2B
| $12.8M | 1.78% | 499,566 -86,986 | -15% | -$2.22M |
|
|
4
Arcus Biosciences
RCUS
$1.13B
| $11.4M | 1.59% | 744,000 +599,000 | +413% | +$9.16M |
|
|
5
Viridian Therapeutics
VRDN
$1.5B
| $11.4M | 1.59% | +499,977 | New | +$11.4M |
|
6
Insmed
INSM
$28.8B
| $11.3M | 1.58% | 154,835 +107,000 | +224% | +$7.81M |
|
|
7
Soleno Therapeutics
SLNO
$3.6B
| $11.2M | 1.56% | 221,437 -224,014 | -50% | -$11.3M |
|
|
8
Ultragenyx Pharmaceutical
RARE
$2.89B
| $9.94M | 1.39% | +179,000 | New | +$9.94M |
|
|
9
Avalo Therapeutics
AVTX
$122M
| $9.22M | 1.29% | 970,359 +915,629 | +1,673% | +$8.7M |
|
10
Cytokinetics
CYTK
$4.23B
| $8.98M | 1.25% | 170,147 | – | – |
|
|
11
Spyre Therapeutics
SYRE
$996M
| $8.89M | 1.24% | +302,247 | New | +$8.89M |
|
12
Catalyst Pharmaceutical
CPRX
$2.52B
| $8.31M | 1.16% | 417,850 -100,536 | -19% | -$2M |
|
|
TECX
13
Tectonic Therapeutic, Inc. Common Stock
TECX
$478M
| $8.09M | 1.13% | 267,145 +204,309 | +325% | +$6.19M |
|
|
BPMC
14
DELISTED
Blueprint Medicines
BPMC
| $7.86M | 1.1% | +85,000 | New | +$7.86M |
|
15
BridgeBio Pharma
BBIO
$9.89B
| $7.27M | 1.01% | 285,613 -46,400 | -14% | -$1.18M |
|
|
16
Sarepta Therapeutics
SRPT
$1.78B
| $6.77M | 0.94% | 54,176 -149,436 | -73% | -$18.7M |
|
17
Corbus Pharmaceuticals
CRBP
$115M
| $5.87M | 0.82% | 284,715 -24,825 | -8% | -$512K |
|
18
Nurix Therapeutics
NRIX
$714M
| $5.84M | 0.81% | 260,000 -180,500 | -41% | -$4.06M |
|
|
19
Nuvalent
NUVL
$5.52B
| $5.34M | 0.75% | 52,238 -99,363 | -66% | -$10.2M |
|
20
Structure Therapeutics
GPCR
$1.11B
| $5.06M | 0.71% | +115,200 | New | +$5.06M |
|
21
Relay Therapeutics
RLAY
$619M
| $4.91M | 0.68% | +693,350 | New | +$4.91M |
|
|
LENZ
22
LENZ Therapeutics
LENZ
$1.1B
| $4.86M | 0.68% | 204,513 | – | – |
|
23
Capricor Therapeutics
CAPR
$287M
| $4.56M | 0.64% | +300,000 | New | +$4.56M |
|
24
Wave Life Sciences
WVE
$1.53B
| $4.46M | 0.62% | 544,265 -30,823 | -5% | -$253K |
|
25
Rezolute
RZLT
$619M
| $4.3M | 0.6% | 887,230 -16,514 | -2% | -$80.1K |
|